Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05052372 · ClinicalTrials.gov registry record
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
A clinical trial, sponsored by xCures.
- Terminated
- Registry status
- 2
- Enrollment target
NCT05052372 is a clinical trial that was terminated before completion, run by xCures. The registered enrollment target is 2 participants.
The verdict
NCT05052372 was terminated before completion, sponsored by xCures.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
Bladder cancers are associated with genetic mutations that are present in the patient's bladder or urothelium, the lining of the lower urinary tract. Fibroblast growth factor (FGFR) alterations are present in approximately one in five patients with recurrent and refractory bladder cancer. This study will collect biomarker data from subjects receiving erdafitinib to further investigate the relationship between treatment with erdafitinib and clinical response, progression, and/or genetic alterations.
Interventions
- DRUG Balversa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-11-21 |
| Est. Completion | 2022-12-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05052372
The ClinicalTrials.gov registry entry for NCT05052372 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is xCures, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Balversa is the first listed.
NCT05052372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05052372 about?
NCT05052372 is a clinical study titled "Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib". Bladder cancers are associated with genetic mutations that are present in the patient's bladder or urothelium, the lining of the lower urinary tract. Fibroblast growth factor (FGFR) alterations are present in approximately one in five patients with recurrent and refractory bladder cancer. This stud...
What is the current status of trial NCT05052372?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2021-11-21. Estimated completion is 2022-12-20.
What interventions are being tested in trial NCT05052372?
The interventions under investigation include: Balversa (DRUG).
Who is sponsoring clinical trial NCT05052372?
This trial is sponsored by xCures, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.